21/09/2026 PureTech Secures FDA Alignment and Fast Track Designation for LYT-200 in Relapsed/Refractory High-Risk MDS PureTech Secures FDA Alignment and Fast Track Designation for LYT-200 in Relapsed/Refractory High-Risk MDS (Ref) PureTech announced a positive regulatory milestone for its investigational therapy, LYT-200 (anti-Gal-9), including successful FDA alignment on its development path and receipt of Fast Track Designation in relapsed/refractory high-risk myelodysplast